Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Anorectic Market Withdrawal Stalled By Appeal; Phentermine Is Removed

Executive Summary

The European withdrawal of diethylproprion will be delayed on appeal as the EU moves to remove amphetamine-like diet drugs from the market.

You may also be interested in...



EMEA anorectic withdrawals

Celltech and other phentermine manufacturers are considering European Court appeal of the EMEA decision to withdraw the diet drug, but have not done so yet. The company, along with other anorectic drug makers, made a formal appeal to EMEA to prevent withdrawal of the products due to an unfavorable risk/benefit profile, which was rejected (1"The Pink Sheet" April 17, p. 19)

EMEA anorectic withdrawals

Celltech and other phentermine manufacturers are considering European Court appeal of the EMEA decision to withdraw the diet drug, but have not done so yet. The company, along with other anorectic drug makers, made a formal appeal to EMEA to prevent withdrawal of the products due to an unfavorable risk/benefit profile, which was rejected (1"The Pink Sheet" April 17, p. 19)

Uprima Selective ED Population Should Be Reflected In Labeling, Cmte. Says

TAP's Uprima labeling should describe the selective population of men with erectile dysfunction who were enrolled in clinical trials of the drug, FDA's Reproductive Health Drugs Committee Urologics Subcommittee said April 10.

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel